{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:08:32Z","timestamp":1791562112927,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13300-021-01085-z","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T04:11:09Z","timestamp":1622261469000},"page":"1791-1797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Role of Finerenone in the Management of Diabetic Nephropathy"],"prefix":"10.1007","volume":"12","author":[{"given":"Stavroula","family":"Veneti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-1594","authenticated-orcid":false,"given":"Konstantinos","family":"Tziomalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"key":"1085_CR1","doi-asserted-by":"publisher","first-page":"3146524","DOI":"10.1155\/2017\/3146524","volume":"2017","author":"S Oltean","year":"2017","unstructured":"Oltean S, Coward R, Collino M, Baelde H. Diabetic nephropathy: novel molecular mechanisms and therapeutic avenues. Biomed Res Int. 2017;2017:3146524.","journal-title":"Biomed Res Int"},{"key":"1085_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.vph.2013.01.001","volume":"58","author":"MK Arora","year":"2013","unstructured":"Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vasc Pharmacol. 2013;58:259\u201371.","journal-title":"Vasc Pharmacol"},{"key":"1085_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","volume":"28","author":"L Tonneijck","year":"2017","unstructured":"Tonneijck L, Muskiet MHA, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28:1023\u201339.","journal-title":"J Am Soc Nephrol"},{"key":"1085_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.ackd.2014.03.007","volume":"21","author":"SM Marshall","year":"2014","unstructured":"Marshall SM. Natural history and clinical characteristics of CKD in type\u00a01 and type\u00a02 diabetes mellitus. Adv Chronic Kidney Dis. 2014;21:267\u201372.","journal-title":"Adv Chronic Kidney Dis"},{"key":"1085_CR5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1085_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nephro.2018.02.007","volume":"14","author":"P Rossing","year":"2018","unstructured":"Rossing P, Persson F, FrimodEt-M\u00f8ller M. Prognosis and treatment of diabetic nephropathy: recent advances and perspectives. Nephrol Ther. 2018;14:31\u20137.","journal-title":"Nephrol Ther"},{"issue":"Suppl 1","key":"1085_CR7","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2337\/dc21-S011","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(Suppl 1):S151\u201367.","journal-title":"Diabetes Care"},{"key":"1085_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13969","volume":"22","author":"J Barrera-Chimal","year":"2020","unstructured":"Barrera-Chimal J, Jaisser F. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. Diabetes Obes Metab. 2020;22:16\u201331.","journal-title":"Diabetes Obes Metab"},{"key":"1085_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","volume":"22","author":"JS Rico-Mesa","year":"2020","unstructured":"Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS. Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep. 2020;22:140.","journal-title":"Curr Cardiol Rep"},{"key":"1085_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152\u201361.","journal-title":"Eur Heart J"},{"key":"1085_CR11","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46:1546\u201355.","journal-title":"Drug Metab Dispos"},{"key":"1085_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30:172\u201384.","journal-title":"Fundam Clin Pharmacol"},{"key":"1085_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","volume":"31","author":"CS Cook","year":"2003","unstructured":"Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003;31:1448\u201355.","journal-title":"Drug Metab Dispos"},{"key":"1085_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29:342\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1085_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13318-020-00610-y","volume":"45","author":"R Heinig","year":"2020","unstructured":"Heinig R, Gerisch M, Bairlein M, Nagelschmitz J, Loewen S. Results from drug\u2013drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications. Eur J Drug Metab Pharmacokinet. 2020;45:433\u201344.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1085_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","volume":"44","author":"R Heinig","year":"2019","unstructured":"Heinig R, Lambelet M, Nagelschmitz J, Alatrach A. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with mild or moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2019;44:619\u201328.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1085_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5:488\u2013501.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1085_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000506275","volume":"51","author":"M Gil-Ortega","year":"2020","unstructured":"Gil-Ortega M, Vega-Mart\u00edn E, Mart\u00edn-Ramos M, et al. Finerenone reduces intrinsic arterial stiffness in Munich Wistar fr\u00f6mter rats, a genetic model of chronic kidney disease. Am J Nephrol. 2020;51:294\u2013303.","journal-title":"Am J Nephrol"},{"key":"1085_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","volume":"9","author":"R Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","unstructured":"Gonz\u00e1lez-Bl\u00e1zquez R, Somoza B, Gil-Ortega M, et al. Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front Pharmacol. 2018;9:1131.","journal-title":"Front Pharmacol"},{"key":"1085_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018;93:1344\u201355.","journal-title":"Kidney Int"},{"key":"1085_CR21","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017;69:870\u20138.","journal-title":"Hypertension"},{"key":"1085_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1681\/ASN.2016040477","volume":"28","author":"J Barrera-Chimal","year":"2017","unstructured":"Barrera-Chimal J, Andr\u00e9-Gr\u00e9goire G, Cat AND, et al. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1. J Am Soc Nephrol. 2017;28:1216\u201326.","journal-title":"J Am Soc Nephrol"},{"key":"1085_CR23","doi-asserted-by":"publisher","first-page":"12450","DOI":"10.1096\/fj.202000164R","volume":"34","author":"V Marzolla","year":"2020","unstructured":"Marzolla V, Feraco A, Gorini S, et al. The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway. FASEB J. 2020;34:12450\u201365.","journal-title":"FASEB J"},{"key":"1085_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1085_CR25","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"1085_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type\u00a02 diabetes mellitus and diabetic nephropathy. J Diabetes Complicat. 2017;31:758\u201365.","journal-title":"J Diabetes Complicat"},{"key":"1085_CR27","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"1085_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type\u00a02 diabetes. Circulation. 2021;143:540\u201352.","journal-title":"Circulation"},{"key":"1085_CR29","doi-asserted-by":"publisher","first-page":"e13413","DOI":"10.1111\/ijcp.13413","volume":"73","author":"C Zuo","year":"2019","unstructured":"Zuo C, Xu G. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: a meta-analysis. Int J Clin Pract. 2019;73:e13413.","journal-title":"Int J Clin Pract"},{"key":"1085_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50:345\u201356.","journal-title":"Am J Nephrol"},{"key":"1085_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","volume":"168","author":"D Lavall","year":"2019","unstructured":"Lavall D, Jacobs N, Mahfoud F, Kolkhof P, B\u00f6hm M, Laufs U. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem Pharmacol. 2019;168:173\u201383.","journal-title":"Biochem Pharmacol"},{"key":"1085_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","volume":"121","author":"B Bonnard","year":"2018","unstructured":"Bonnard B, Pieronne-Deperrois M, Djerada Z, et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J Mol Cell Cardiol. 2018;121:124\u201333.","journal-title":"J Mol Cell Cardiol"},{"key":"1085_CR33","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/dom.13393","volume":"20","author":"M Lachaux","year":"2018","unstructured":"Lachaux M, Barrera-Chimal J, Nicol L, et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes Metab. 2018;20:2399\u2013407.","journal-title":"Diabetes Obes Metab"},{"key":"1085_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71:599\u2013608.","journal-title":"Hypertension"},{"key":"1085_CR35","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453\u201363.","journal-title":"Eur Heart J"},{"key":"1085_CR36","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37:2105\u201314.","journal-title":"Eur Heart J"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01085-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:21:27Z","timestamp":1625703687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01085-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01085-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}